Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

OBJECTIVES:

- Determine the optimal criteria for determination of ototoxicity in younger cancer
patients treated with cisplatin.

- Determine the feasibility of including ultrahigh frequency and evoked otoacoustic
emission testing as adjunctive measures of ototoxicity.

- Determine the feasibility and necessity of central review of audiometry data.

OUTLINE: This is a multicenter, prospective, cohort study.

Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic
emission testing) before the first course of planned cisplatin, before each subsequent
course of cisplatin, and 4 weeks after the last dose of cisplatin.

Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation
undergo hearing tests before the transplantation and 4 weeks after transplantation.

PROJECTED ACCRUAL: A total of 282 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

- Planning to undergo treatment with any cisplatin-containing therapeutic regimen for
cancer

- Treatment does not need to be on a COG therapeutic study

- Planning to enroll on clinical trial ACCL0431

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior cisplatin